Primary CNS Lymphoma

Current Hematologic Malignancy Reports 9, 243-253 DOI: 10.1007/s11899-014-0217-2

Citation Report

#	Article	IF	CITATIONS
1	Primary CNS lymphoma: in search of the evidence. Lancet Haematology,the, 2015, 2, e227-e228.	2.2	3
2	Diagnosis and treatment of primary central nervous system lymphoma: A report of nine cases and literature review. Oncology Letters, 2015, 9, 1795-1801.	0.8	3
3	Salvage chemotherapy with R-BAD (rituximab, bendamustine, cytarabine, and dexamethasone) for the treatment of relapsed primary CNS lymphoma. Blood Research, 2016, 51, 285.	0.5	1
4	Enhanced MRI and 18F-FDG PET/CT Findings of Primary Central Nervous System Lymphoma Mimicking Encephalitis. Clinical Nuclear Medicine, 2016, 41, e436-e438.	0.7	4
5	Pathology of Extranodal Lymphoma. Radiologic Clinics of North America, 2016, 54, 639-648.	0.9	2
6	How we diagnose and treat vitreoretinal lymphoma. British Journal of Haematology, 2016, 173, 680-692.	1.2	113
7	Primary vitreoretinal lymphoma. Current Opinion in Ophthalmology, 2016, 27, 177-184.	1.3	38
8	Characteristics and outcome of patients with primary CNS lymphoma in a "real-life―setting compared to a clinical trial. Annals of Hematology, 2016, 95, 793-799.	0.8	31
9	Update on Brain Tumors: New Developments in Neuroâ€oncologic Diagnosis and Treatment, and Impact on Rehabilitation Strategies. PM and R, 2016, 8, 678-689.	0.9	14
10	Neurosurgery and human immunodeficiency virus in the era of combination antiretroviral therapy: a review. Journal of Neurosurgery, 2017, 126, 897-907.	0.9	2
11	Population-based experience on primary central nervous system lymphoma 2000–2012: the incidence is increasing. Acta Oncológica, 2017, 56, 599-607.	0.8	27
12	High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom. Bone Marrow Transplantation, 2017, 52, 1268-1272.	1.3	18
13	Primary central nervous system lymphoma: essential points in diagnosis and management. Medical Oncology, 2017, 34, 61.	1.2	23
14	B-cell posttransplant lymphoproliferative disorder isolated to the central nervous system is Epstein-Barr virus positive and lacks p53 and Myc expression by immunohistochemistry. Human Pathology, 2017, 61, 140-147.	1.1	6
15	Role of radiation therapy in primary central nervous system lymphoma. Journal of Neuro-Oncology, 2017, 135, 629-638.	1.4	11
16	Frequency of <i>MYD88</i> and <i>CD79B</i> mutations, and <i>MGMT</i> methylation in primary central nervous system diffuse large <scp>B</scp> â€cell lymphoma. Neuropathology, 2017, 37, 509-516.	0.7	41
17	Primary Vitreoretinal Lymphoma—A Review. Asia-Pacific Journal of Ophthalmology, 2017, 6, 283-289.	1.3	38
18	Neural Tumors of the Orbit—What Is New?. Asia-Pacific Journal of Ophthalmology, 2017, 6, 273-282.	1.3	8

TATION REPO

IF ARTICLE CITATIONS # Assessing the Safety of Craniotomy for Resection of Primary Central Nervous System Lymphoma: A 19 1.1 13Nationwide Inpatient Sample Analysis. Frontiers in Neurology, 2017, 8, 478. The possible role of maintenance treatment for primary central nervous system lymphoma. Blood Reviews, 2018, 32, 378-386. 2.8 Intraoperative Flow Cytometry Enables the Differentiation of Primary Central Nervous System 22 0.7 18 Lymphoma from Glioblastomá. World Neurosurgery, 2018, 112, e261-e268. A Rare Case of Spontaneous Remission and Relapse of a Primary Central Nervous System Lymphoma. Acta Medica Portuguesa, 2018, 31, 777. Adrenal relapse of primary central nervous system diffuse large B-cell lymphoma. Medicine (United) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 24

CITATION REPORT

25	Cerebellar large B-cell lymphoma: a case report. Journal of Medical Case Reports, 2018, 12, 341.	0.4	5
26	Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches. Bioconjugate Chemistry, 2018, 29, 3937-3966.	1.8	23
27	Diffuse Large B-cell Lymphoma Subtypes. , 2018, , 571-582.		0
28	Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL). BMC Cancer, 2018, 18, 729.	1.1	6
29	B cell-rich non-neoplastic sentinel lesion preceding primary central nervous system lymphoma. Diagnostic Pathology, 2018, 13, 37.	0.9	7
30	Pocket Guide to Diagnostic Hematopathology. , 2019, , .		1
31	Whole Tumor Histogram Analysis Using DW MRI in Primary Central Nervous System Lymphoma Correlates with Tumor Biomarkers and Outcome. Cancers, 2019, 11, 1506.	1.7	11
32	Solitary intraventricular Hodgkin lymphoma post-transplant lymphoproliferative disease (HL-PTLD): Case report. Journal of Clinical Neuroscience, 2019, 69, 269-272.	0.8	4
33	Seizures in patents with primary central nervous system lymphoma: Prevalence and associated features. Journal of the Neurological Sciences, 2019, 400, 34-38.	0.3	10
34	Primary Central Nervous System Lymphoma in an Immunocompetent Patient Presenting as Multiple Cerebellar Lesions: A Case Report and Review of Literature. Journal of Investigative Medicine High Impact Case Reports, 2019, 7, 232470961989354.	0.3	2
35	Allogeneic stem cell transplantation for relapsed primary central nervous system lymphoma: Is it feasible?. Hematology/ Oncology and Stem Cell Therapy, 2019, 12, 220-225.	0.6	11
36	Low ADC in CNS Lymphoma. Clinical Nuclear Medicine, 2020, 45, 545-546.	0.7	0
37	Diffuse Large B-Cell Lymphoma of the Central Nervous System Manifesting with Intratumoral Hemorrhage: A Case Report and Literature Review. World Neurosurgery, 2020, 143, 490-494.	0.7	3

#	Article	IF	CITATIONS
38	High-dose methotrexate-based regimens with or without vincristine for the treatment of primary central nervous system lymphoma. Neuro-Oncology Advances, 2020, 2, vdaa077.	0.4	2
39	Neuro-Ophthalmic Manifestations of Intracranial Malignancies. Journal of Neuro-Ophthalmology, 2020, 40, e31-e48.	0.4	8
40	Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy. Japanese Journal of Clinical Oncology, 2020, 50, 999-1008.	0.6	4
41	Approach to the patient with CNS lymphoma. , 2021, , 172-185.		1
42	Epstein-Barr Virus-Positive Primary Central Nervous System Lymphoma in a 40-Year-Old Immunocompetent Patient. Cureus, 2021, 13, e12754.	0.2	6
43	Diagnosis, prognosis and treatment of primary central nervous system lymphoma in the elderly population (Review). International Journal of Oncology, 2021, 58, 371-387.	1.4	18
44	Downregulation of USP18 reduces tumor-infiltrating activated dendritic cells in extranodal diffuse large B cell lymphoma patients. Aging, 2021, 13, 14131-14158.	1.4	6
45	Neurologic Complications of Human Immunodeficiency Virus. CONTINUUM Lifelong Learning in Neurology, 2021, 27, 963-991.	0.4	1
46	A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups. Frontiers in Oncology, 2021, 11, 696147.	1.3	10
47	Filtration-Histogram Based Magnetic Resonance Texture Analysis (MRTA) for the Distinction of Primary Central Nervous System Lymphoma and Glioblastoma. Journal of Personalized Medicine, 2021, 11, 876.	1.1	6
49	Management of Primary Central Nervous System Lymphoma UsingÂIntra-Arterial Chemotherapy With Osmotic Blood-Brain Barrier Disruption: Retrospective Analysis of the Sherbrooke Cohort. Frontiers in Oncology, 2020, 10, 543648.	1.3	9
50	Primary central nervous system T-cell lymphoma: An analysis from the surveillance, epidemiology, and end results program. Journal of Clinical Neuroscience, 2020, 79, 74-79.	0.8	4
51	Primary Diffuse Large B-Cell Lymphoma of Central Nervous System: Is Still Surgery an Unorthodox Treatment?. Journal of Clinical Medicine Research, 2015, 7, 1007-1012.	0.6	7
52	An Autopsy Case of Epstein-Barr Virus–Associated Diffuse Large B-Cell Lymphoma of the Central Nervous System in an Immunocompromised Host. Journal of Pathology and Translational Medicine, 2018, 52, 51-55.	0.4	1
53	PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS. Romanian Journal of Neurology/ Revista Romana De Neurologie, 2015, 14, 77-84.	0.1	0
54	Primary Cns Lymphoma: Current Diagnosis and Management. Journal of Cancer Prevention & Current Research, 2016, 4, .	0.1	0
56	Lymphomas. , 2019, , 1881-1922.		0
57	Diffusion-weighted MR imaging histogram analysis in HIV positive and negative patients with primary central nervous system lymphoma as a predictor of outcome and tumor proliferation. Oncotarget, 2020, 11, 4093-4103.	0.8	1

CITATION REPORT

c		ON	Dr		DT
	AI	ION	- KE	PO.	IK I

#	Article	IF	CITATIONS
58	Primer santral sinir sistemi lenfomaları: 10 vakanın retrospektif analizi Pamukkale Medical Journal, 0, , .	0.2	0
59	All-cause and tumor-specific mortality trends in elderly primary central nervous system lymphoma (PCNSL) patients: a surveillance, epidemiology, and end results (SEER) analysis. Journal of Neurosurgical Sciences, 2024, 68, .	0.3	5
60	Primary central nervous system lymphoma high incidence and poor survival in Finnish population-based analysis. BMC Cancer, 2022, 22, 236.	1.1	6
61	Protein kinase c delta expression in primary central nervous system lymphomas. Journal of Hematopathology, 0, , 1.	0.2	0
63	Clinical pathology of primary central nervous system lymphoma in HIV-positive patients-a 41 Chinese patients retrospective study. Annals of Diagnostic Pathology, 2023, 63, 152108.	0.6	1
64	Pretreatment findings on magnetic resonance imaging in primary central nervous system lymphoma may predict overall survival duration. Neuroradiology Journal, 2023, 36, 479-485.	0.6	2
65	Primary Central Nervous System Lymphoma: Neuro-Oncologic Approach. Essentials in Ophthalmology, 2023, , 93-101.	0.0	0